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ABSTRACT
CONTEXT AND OBJECTIVES: Anemia is the most frequent extraintestinal complication of inflammatory 
bowel disease. This study aimed to: 1) determine the prevalence of anemia among patients with inflam-
matory bowel disease; 2) investigate whether routine laboratory markers are useful for diagnosing anemia; 
and 3) evaluate whether any association exists between anemia and clinical/laboratory variables.
DESIGN AND SETTING: Cross-sectional at a federal university.
METHODS: 44 outpatients with Crohn’s disease and 55 with ulcerative colitis were evaluated. Clinical vari-
ables (disease activity index, location of disease and pharmacological treatment) and laboratory variables 
(blood count, iron laboratory, vitamin B12 and folic acid) were investigated.
RESULTS: Anemia and/or iron laboratory disorders were present in 75% of the patients with Crohn’s 
disease and in 78.2% with ulcerative colitis. Anemia was observed in 20.5% of the patients with 
Crohn’s disease and in 23.6% with ulcerative colitis. Iron-deficiency anemia was highly prevalent in patients 
with Crohn’s disease (69.6%) and ulcerative colitis (76.7%). Anemia of chronic disease in combination with 
iron deficiency anemia was present in 3% of the patients with Crohn’s disease and in 7% of the patients 
with ulcerative colitis. There was no association between anemia and disease location. In ulcerative colitis, 
anemia was associated with the disease activity index.
CONCLUSIONS: Most patients present iron laboratory disorders, with or without anemia, mainly due to 
iron deficiency. The differential diagnosis between the two most prevalent types of anemia was made 
based on clinical data and routine laboratory tests. In ulcerative colitis, anemia was associated with the 
disease activity index.
RESUMO
CONTEXTO E OBJETIVOS: Anemia é a mais frequente complicação extraintestinal na doença inflamatória 
intestinal. Este estudo objetivou: 1) determinar a prevalência de anemia em portadores de doença infla-
matória intestinal; 2) investigar se os marcadores laboratoriais de uso rotineiro são úteis para o diagnóstico 
da anemia; 3) avaliar se existe associação entre anemia e variáveis clínico-laboratoriais.
TIPO DE ESTUDO E LOCAL: Estudo transversal em uma universidade federal.
MÉTODOS: Foram avaliados 44 pacientes ambulatoriais com doença de Crohn e 55 com retocolite ul-
cerativa. Foram investigados aspectos clínicos (índice de atividade da doença, localização da doença e 
tratamento farmacológico) e laboratoriais (hemograma, ferrocinética, vitamina B12 e ácido fólico).
RESULTADOS: Anemia e/ou anormalidades na ferrocinética estavam presentes em 75% dos pacientes 
com doença de Crohn e em 78,2% dos pacientes com retocolite. Anemia foi observada em 20,5% do 
grupo com doença de Crohn e em 23,6% do grupo com retocolite. Anemia por deficiência de ferro predo-
minou entre os pacientes com doença de Crohn (69,6%) e com retocolite (76,7%). Anemia de doença crô-
nica associada à anemia ferropriva estava presente em 3% dos pacientes com doença de Crohn e em 7% 
daqueles com retocolite. Na retocolite, a anemia estava associada com o índice de atividade da doença.
CONCLUSÕES: A maioria dos pacientes apresentava alterações na ferrocinética com ou sem anemia, prin-
cipalmente decorrente da ferropenia. O diagnóstico diferencial entre os dois tipos mais prevalentes de 
anemia foi baseado nos dados clínicos e nos testes laboratoriais de rotina. Anemia estava associada com 
o índice de atividade na retocolite.
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INTRODUCTION
Inflammatory bowel diseases (IBD) comprise two main dis-
tinct clinical entities: Crohn’s disease (CD) and ulcerative colitis 
(UC). CD is a chronic transmural inflammation that can affect 
any segment of the digestive tract and is associated with numer-
ous extraintestinal manifestations.1 UC is the result of chronic 
inflammation of the colon, affecting one or more of its segments. 
Generally, the distal segments are affected and all viscera and the 
distal ileum may eventually be involved.2,3
For a long time, anemia has been considered to be an inev-
itable complication of CD and UC and its treatment has only 
recently become a specific objective for the management of such 
individuals.4 Gasché et al.5 showed that 33% of patients with CD 
had anemia [defined as hemoglobin (Hb) < 12 g/dl]. Another 
study reported a prevalence of anemia (Hb < 10 g/dl) of 26% in 
CD and of 37% in UC.6
Iron deficiency is the most common type of anemia and 
is generally underdiagnosed. Chronic and occult blood loss 
through the gastrointestinal tract is the most frequent cause of 
iron deficiency.7 Malabsorption of iron is uncommon, unless the 
proximal digestive tract is extensively affected by CD.4,8
Anemia of chronic disease (ACD) is the second most frequent 
type of anemia in IBD.4,9 This condition is characterized by rela-
tive deficiency of erythropoietin which is slightly greater, although 
still very little in relation to the degree of anemia, when compared 
with anemia of the same intensity observed in other etiologies.6,9 
Cytokines such as interleukin 1 (IL-1), tumor necrosis factor 
(TNF) and interferon-γ are produced in larger amounts by mono-
cytes and mononuclear cells of the intestinal lamina propria.6 IL-1 
and interferon-γ decrease the production of erythropoietin and 
inhibit erythropoiesis. TNF and IL-1 increase the production of 
ferritin, thus reducing the amount of iron available for erythro-
poiesis.10 Moreover, some in vitro and in vivo studies have dem-
onstrated that these cytokines induce resistance to erythropoie-
tin in erythroid precursors.6,11,12 In 2000, a peptide synthesized in 
the liver, called hepcidin, was isolated from plasma. Expression of 
this peptide is induced by lipopolysaccharide and IL-6. This pep-
tide increases the capacity of reticuloendothelial cells in the duo-
denal crypts to take up and retain iron and decreases dietary iron 
absorption.13,14 Hepcidin exerts its biological function upon bind-
ing to the only known cellular iron exporter, ferroportin, thereby 
leading to ferroportin internalization and degradation. This event 
blocks transfer of the absorbed iron from the duodenal enterocyte 
into the circulation and, in parallel, causes retention of iron inside 
macrophages and monocytes.15 
Other causes of anemia, such as vitamin B12 deficiency, gener-
ally occur when resection of the ileum exceeds 60 cm. Inadequate 
ingestion, malabsorption and use of sulfasalazine or methotrex-
ate contribute towards emergence of megaloblastic anemia due 
to folic acid deficiency. In addition, drugs such as immunosup-
pressants, mesalazine and sulfasalazine can cause bone marrow 
suppression.4,16 Some studies have demonstrated that treatment 
of anemia has a positive impact on the quality of life of patients 
with IBD.17,18
The differential diagnosis between iron-deficiency anemia 
(IDA) and ACD is important since only the former will respond 
solely to replacement therapy. Moreover, evidence indicates that 
administration of iron to patients with chronic inflammation 
may trigger an increase in production of oxygen free radicals, 
thus propagating tissue injury.8,10,19,20
The high prevalence of anemia among patients with IBD 
observed in the international literature encouraged the present 
investigation conducted on Brazilian patients with IBD. Although 
this abnormality is highly common, its diagnosis and treatment 
have not received the same attention by physicians as have other 
complications such as arthritis and osteopathy.20-22 Another 
objective was to determine whether or not it is possible to estab-
lish the etiology of anemia using noninvasive complementary 
tests that are widely available in clinical practice. In addition, we 
evaluated whether the presence of these abnormalities is associ-
ated with clinical and/or laboratory activity, location of the dis-
ease and medications used.
OBJECTIVES
1. To determine the prevalence of anemia in a group of Brazilian 
patients with inflammatory bowel disease; 
2. To investigate whether routine laboratory markers are useful 
for the etiological diagnosis of anemia; 
3. To evaluate the association between anemia and clinical/lab-
oratory variables.
METHODS
Forty-four patients with CD and 55 with UC, who were being 
regularly followed up at the intestinal sector of the gastroenterol-
ogy outpatient clinic of a federal university hospital in São Paulo, 
Brazil, were studied. The diagnoses of Crohn’s disease and ulcer-
ative colitis were based on the usual clinical criteria.1,2 Patients 
were included as they visited the clinic and if they met the inclu-
sion criteria, from March 2001 to May 2002. Patients with known 
hemoglobinopathies, myelodysplastic syndromes, sideroblastic 
anemia, kidney failure, liver disease and hypothyroidism, and 
patients requiring hospital admission were excluded.
The study protocol was approved by the hospital’s ethics 
committee, and all patients or their legal representatives signed 
an informed consent form to participate in the study.
The Harvey and Bradshaw index23 and the Truelove and 
Witts index24 were used to quantify clinical disease activity in 
patients with CD and UC, respectively. The disease location 
ORIGINAL ARTICLE | Alves RA, Miszputen SJ, Figueiredo MS
142     Sao Paulo Med J. 2014; 132(3):140-6
in CD was defined by the Vienna classification of Crohn’s dis-
ease.25 Blood was collected during regular pharmacological 
treatment (aminosalicylates, corticosteroids, antibiotics and/or 
immunomodulators). Iron supplementation was discontinued 
for at least one week before blood collection in patients tak-
ing oral iron and for one month in those receiving parenteral 
iron.26 The following laboratory parameters were evaluated: com-
plete blood count, erythrocyte sedimentation rate, reticulocyte 
count, serum iron, transferrin concentration, ferritin, bilirubins, 
lactate dehydrogenase, vitamin B12 and folic acid. The transfer-
rin saturation was calculated according to the formula of Turati 
et al.27 Hemoglobin electrophoresis was carried out in the cases of 
patients with microcytosis and normal serum iron.28-30
Anemia was defined as Hb levels of less than 13 g/dl in males 
and less than 12 g/dl in females.31 Iron deficiency was defined 
based on reduced serum ferritin concentration (< 30 ng/ml) and/
or low transferrin saturation (< 16%). In the presence of clini-
cal or biochemical evidence of inflammation, the lower limit of 
serum ferritin consistent with normal iron stores was 100 ng/dl. 
The diagnostic criteria for ACD were serum ferritin > 100 ng/ml 
and transferrin saturation < 16%, in the presence of biochemical 
or clinical evidence of inflammation. The definition of functional 
iron deficiency (FID) was the same, but with Hb levels within 
the normal range. The association between IDA and ACD was 
characterized by transferrin saturation < 16% and serum ferritin 
between 30 and 100 ng/dl.32 Macrocytosis was defined as a mean 
corpuscular volume > 95.1 fl in males and > 98.3 fl in females.
The term hematological abnormality was used to define alter-
ations in iron laboratory values (relating to iron deficiency or to 
functional iron deficiency observed in chronic diseases), with or 
without associated red blood cell abnormalities. This term was 
also used when referring to macrocytosis. 
By accepting an alpha of 5% with statistical power of 90% and 
anemia as the main outcome, a sample of 37 cases for each group 
of diseases was estimated. A virtual calculator was used, which 
was obtained through the following site: http://www.lee.dante.br/
pesquisa/amostragem/amostra.html.
Statistical analysis
The statistical analysis was performed using the Statistical 
Package for the Social Sciences (SPSS) for Windows software, 
versions 10.0.1 and 13.0 (SPSS, Chicago, IL, USA). Numerical 
variables were expressed as the mean, median, standard devia-
tion and range. Nominal variables were reported as absolute (n) 
and relative (%) frequencies. Student’s t test was used to compare 
numerical variables between the two groups of patients. Nominal 
variables were compared using the χ2 test or Fisher’s exact test, 
when necessary. The level for rejection of the null hypothesis was 
set at 0.05 or 5%.
RESULTS
Demographic and clinical characteristics
Women predominated in both the CD and the UC group, with no 
significant difference between the groups. No difference in mean 
age was observed between the two groups. With respect to the 
location of the disease, the ileal-colonic (L3) (47.7%) and ileal (L1) 
(40.9%) forms predominated in patients with CD, whereas panco-
litis (34.7%) and rectosigmoid involvement (30.9%) were more fre-
quent in patients with UC (P < 0.01). The prevalence of individuals 
who had previously undergone intestinal and/or colon resection 
was higher among CD patients (61.4%), whereas only two patients 
(3.6%) in the UC group had undergone resection (P < 0.01). Active 
disease was more prevalent among patients of the UC group than 
in those of the CD group (P < 0.01) (Table 1).
Etiology of hematological abnormalities 
and prevalence of anemia
No difference in the etiological factor of hematological abnor-
malities was observed between patients with CD and those with 
Table 1. Demographic and clinical characteristics of the 
patients with Crohn’s disease (CD) and ulcerative colitis (UC)
CD UC P-value
Gender
Male 15 (34.1%) 22 (40.0%)
Female 29 (65.9%) 33 (60.0%)
Total 44 (100%) 55 (100%) P = 0.67*
Age (years)
Mean ± SD 41.6 ± 10.7 43.8 ± 14.0
Median (range) 43 (22-70) 43 (17-81)
95% confidence interval 38.4 - 44.9 40.0 - 47.2 P = 0.40†
Disease location
Ileum (LI)‡ 18 (40.9%) -
Ileum-colon (L3)‡ 21. (47.7%) 1 (1.8%)
Colon (L2)‡ 4 (9.1%) 7 (12.7%)
Pancolitis (L2)‡ 1 (2.3%) 19 (34.7%)
Rectosigmoid - 17 (30.9%)
Rectum - 11 (20%)
Total 44 (100%) 55 (100%) P < 0.01§
Surgical resection
None 17 (38.6%) 53 (96.4%)
Distal ileum 9 (20.5%) -
Ileum 2 (4.5%) -
Right colon 4 (9.1%) -
Ileum and right colon 12 (27.3%) -
Total colectomy - 2 (3.6%)
Total 44 (100%) 55 (100%) P < 0.01§
Disease activity
Active 11 (25%) 47 (85.5%)
Remission 33 (75%) 8 (14.5%)
Total 44 (100%) 55 (100%) P < 0.01*
*Fisher’s exact test; †Student’s t test; ‡Vienna Classification for CD; §χ2 test. 
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UC (P = 0.77). In the CD group, 25% of the patients did not pres-
ent hematological abnormalities. The most frequent types of 
hematological abnormalities were iron deficiency (ID) (without 
anemia) in 45.4% and iron deficiency anemia (IDA) in 24.2%. In 
the UC group, 21.8% of the patients did not present any hemato-
logical abnormality. ID was present in 53.5%, IDA in 23.2 % and 
ID + FID in 9.3% (Table 2). Hemoglobin levels below the lower 
limit of normal were observed in 22 patients, including 9 with 
CD and 13 with UC (P = 0.36) (Table 3).
Associations
Activity versus hematological abnormalities
No association between clinical disease activity and hematologi-
cal abnormalities was observed in patients with CD (P = 0.47) 
(Table 4). In the UC group, 93% (40/43) of the patients with 
hematological abnormalities presented mild or moderate activ-
ity. Three of the eight individuals in remission showed hemato-
logical abnormality (P = 0.03) (Table 5).
Location of the disease versus hematological abnormalities
No association between the location of the disease and the pres-
ence or absence of hematological abnormalities was observed in 
the CD group (P = 0.54) or in the UC group (P = 0.41) (Table 6).
Pharmacological treatment versus hematological abnormalities
No association between the type of pharmacological treatment 
and the presence or absence of hematological abnormalities was 
observed in either group (P = 0.32 in CD and 0.73 in UC) (data 
not shown).
DISCUSSION
Although a high prevalence of anemia among patients with IBD 
has been recognized in the international literature for decades, 
many services do not possess a protocol for its investigation. 
Measurement of hemoglobin levels and serum iron alone is 
insufficient: hemoglobin measurements only allow diagnosing 
of the third and last stage of IDA, while iron measurement does 
not allow differentiation between IDA and ACD. In a study con-
ducted in the 1980s involving hospitalized patients, only 11 of 
the 29 patients initially diagnosed with IDA had iron deficiency 
and most of them actually presented ACD.33 One important fact 
is that iron deficiency is 2 to 5 times more frequent than IDA.31 
Thus, it is possible that the prevalence of iron deficiency is under-
estimated, especially if measurement of serum ferritin is not part 
of the routine diagnosis.
The present study demonstrated that most patients with IBD 
had some type of hematological abnormality, with no difference 
in the distribution of these abnormalities between CD and UC 
(Table 2). A cross-sectional study does not provide information 
about the mean duration of episodes of anemia. However, analy-
sis of these patients provides an overview of the burden of ane-
mia in a population with IBD during the natural history of the 
disease. Among the 22 patients with hemoglobin levels below the 
normal limit, 9 had CD and 13 had UC. The prevalence of anemia 
Table 2. Etiology of hematological abnormalities in patients with 
Crohn’s disease (CD) and ulcerative colitis (UC) (n = 76)
CD UC Total
ID 15 (45.4%) 23 (53.5%) 38 (50.0%)
ID + FID 3 (9.1%) 4 (9.3%) 7 (9.2%)
FID 3 (9.1%) 2 (4.6%) 5 (6.6%)
IDA 8 (24.2%) 10 (23.2%) 18 (23.7%)
IDA + ACD 1 (3.0%) 3 (7.0%) 4 (5.2%)
Macrocytosis 3 (9.1%) 1 (2.3%) 4 (5.2%)
Total 33 (100%) 43 (100%) 76 (100%)
ID = iron deficiency (without anemia); FID = functional iron deficiency (without anemia); 
IDA = iron-deficiency anemia; ACD = anemia of chronic disease. χ2 test. P = 0.77.
Table 3. Prevalence of anemia in male and female patients with Crohn’s 
disease (CD) and ulcerative colitis (UC) (n = 22)
CD UC Total
Male (Hb < 13 g/dl) 1 (4.5%) 4 (18.2%) 5 (22.7%) 
Female (Hb < 12 g/dl) 8 (36.4%) 9 (40.9%) 17 (77.3%) 
Total 9 (40.9%) 13 (59.1%) 22 (100%)
Hb = hemoglobin. Fisher’s exact test; P = 0.36.
Table 4. Association between clinical disease activity and 
hematological abnormalities in patients with Crohn’s disease (n = 44)
Hematological abnormality Activity Remission Total
None 1 (2.3%) 10 (22.7%) 11 (25%)
ID 3 (6.8%) 12 (27.3%) 15 (34.1%)
ID + FID 1 (2.3%) 2 (4.5%) 3 (6.8%)
FID 1 (2.3%) 2 (4.5%) 3 (6.8%)
IDA 3 (6.8%) 5 (11.4%) 8 (18.2%)
IDA + ACD 1 (2.3%) - 1 (2.3%)
Macrocytosis 1 (2.3%) 2 (4.5%) 3 (6.8%)
Total 11 (25%) 33 (75%) 44 (100%)
ID = iron deficiency (without anemia); FID = functional iron deficiency (without anemia); 
IDA = iron-deficiency anemia; ACD = anemia of chronic disease. χ2 test; P = 0.47.
Table 5. Association between clinical-laboratory activity and 
hematological abnormalities in patients with ulcerative colitis (n = 55)
Hematological 
abnormality
Activity
Total
Remission Mild Moderate
None 5 (9.1%) 5 (9.1%) 2 (3.6%) 12 (21.8%)
ID 3 (5.5%) 12 (21.8%) 8 (14.5%) 23 (41.8%)
ID + FID - 3 (5.5%) 1 (1.8%) 4 (7.3%)
FID - 1 (1.8%) 1 (1.8%) 2 (3.6%)
IDA - 2 (3.6%) 8 (14.5%) 10 (18.2%)
IDA + ACD - - 3 (5.5%) 3 (5.5%)
Macro - - 1 (1.8%) 1 (1.8%)
Total 8 (14.5%) 23 (41.8%) 24 (43.6%) 55 (100%)
ID = iron deficiency (without anemia); FID = functional iron deficiency (without 
anemia); IDA = iron-deficiency anemia; ACD = anemia of chronic disease; Macro = 
macrocytosis. χ2 test; P = 0.03.
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was similar in the CD and UC groups (Table 3). Two  aspects 
of this result should be highlighted: first, the predominance of 
female patients (77.3%), which probably reflects their predomi-
nance in the present sample as a whole; second, the lack of a dif-
ference between CD and UC, which might be due to the relatively 
small number of anemic subjects. Therefore, the prevalence of 
anemia observed in this study, i.e. 20.5% among patients with CD 
and 23.6% among patients with UC (data not shown), was lower 
than that reported in some other studies.5,6 However, in a review 
published by Wilson et al.,34 the prevalence of anemia ranged 
from 10.2% to 72.7% among outpatients with CD and from 8.8% 
to 66.6% among patients with UC.
In the CD group, 23/33 patients (69.6%) with hematologi-
cal abnormalities presented some degree of iron deficiency. 
The  same was observed for 33/43 patients (76.7%) of the UC 
group (Table 2). Coexistence of ID + FID was found in 9.1% of 
patients with CD and in 9.3% of the UC group. However, this 
difference was not statistically significant. According to a review 
by Kulnigg and Gasche,7 the prevalence of iron deficiency in 
patients with CD ranged from 36% to 90% according to the sam-
ple studied and to the definition of iron deficiency.
No difference in the prevalence of ACD was observed between 
patients with CD and those with UC (Table 2). ACD associated 
with IDA was present in 3.0% of the patients with CD (1/33) and 
in 7.0% of the patients with UC (3/43). Although ACD is the sec-
ond leading cause of hematological abnormalities in IBD, stud-
ies reporting the true prevalence of this complication are scarce. 
In the study by Schreiber et al.,6 the prevalence of ACD was 15% 
among patients with CD and 10% among those with UC. Lakatos 
et al.35 reported prevalences of 17.7% and 9.6%. In the present 
study functional iron deficiency was presented in 9.1% with CD 
and in 4.6% of the patients with UC.
Coexistence of IDA and ACD has been reported in the lit-
erature mainly for patients with rheumatoid arthritis. Ahluwalia 
et al.36 observed this association in 64% of women over the age 
of 70 years. A recent study among patients with IBD indicated 
that the combination IDA/ACD was the third most frequent 
pathological condition underlying anemia.11 In the present inves-
tigation, this condition was observed in only one patient with CD 
and in three patients with UC (Table 2). We believe that this low 
prevalence is due to the difficulty in detecting this association 
in routine tests. Nevertheless, when both types of hematologi-
cal abnormality occur together, microcytosis is more frequent 
and anemia tends to be more intense. The ratio between soluble 
transferrin receptor concentration and log ferritin level might be 
a useful parameter. A ratio < 1 suggests ACD, whereas a ratio > 2 
suggests iron deficiency coexisting with ACD.14
Four patients who were not anemic had macrocytosis, includ-
ing three women with CD, one of them also presenting iron 
depletion, and one man with UC (Table 2). The mean corpus-
cular volume was 111.9 fl for patients with CD and 97.3 fl for the 
patient with UC (data not shown). Lakatos et al.35 found macro-
cytosis in 4.0% of patients with CD and UC, a prevalence slightly 
lower than that observed in the present study (5.2%) (Table 2). 
One CD patient had a normal serum level of vitamin B12 and low 
folic acid level. The second CD patient presented a low level of 
vitamin B12 and normal level of folic acid. The last patient showed 
normal levels of vitamin B12 and folic acid. The UC patient had 
low levels of vitamin B12 and folic acid (data not shown).
One of the objectives of this investigation was to evaluate asso-
ciations between hematological abnormalities and some clinical 
characteristics of IBD. No association was observed between hema-
tological abnormalities and the clinical activity index in CD, prob-
ably because most patients (75%) were in remission. Interestingly, 
there was a high prevalence of hematological abnormalities in 
patients in remission (69.7%) and in those presenting clinical 
activity (90.9%) (Table 4). In contrast, an association between clin-
ical-laboratory activity and the presence of hematological abnor-
malities was found in the UC group (Table 5), such that 93% of 
the patients with hematological abnormalities presented mild or 
moderate activity, whereas three of the eight patients in remission 
presented hematological abnormalities (iron deficiency as etiol-
ogy). The other patients with iron deficiency, as well the patients 
with ACD, FID and the patient with macrocytosis, presented mild 
Table 6. Association between disease location and hematological abnormalities in patients with Crohn’s disease (CD) and ulcerative 
colitis (UC)
Location
CD UC
With hematological 
abnormalities
Without hematological 
abnormalities
With hematological 
abnormalities
Without hematological 
abnormalities
Ileum 13 (29.5%) 5 (11.4%) – –
Ileum-colon 17 (38.6%) 4 (9.1%) 1 (1.8%) –
Colon 2 (4.5%) 2 (4.5%) 6 (10.9%) 1 (1.8%)
Pancolitis 1 (2.3%) – 17 (30.9%) 2 (3.6%)
Rectosigmoid – – 11 (20.0%) 6 (10.9%)
Rectum – – 8 (14.5%) 3 (5.5%)
Total 33 (75%) 11 (25%) 43 (78.2%) 12 (21.8%)
χ2 test; CD: P = 0.54; UC: P = 0.41.
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or moderate activity. Since  the Truelove-Witts index24 is influ-
enced by Hb, this result is not unexpected. Gasché et al.5 studied a 
group of 49 patients with CD and did not observe any difference 
in the activity index between patients with and without anemia. 
Similar results were obtained in the present study, although those 
authors used the CDAI and we chose to use the Harvey-Bradshaw 
index. However, other authors6,11 have demonstrated an associa-
tion between the severity of anemia and disease activity indices in 
CD and UC patients.
Another intriguing finding was the possibility of an associa-
tion between the location of IBD and hematological abnormali-
ties. No such association was observed in the CD group or in the 
UC group (Table 6). In the latter group, 39.5% of the patients 
with hematological abnormalities had pancolitis, whereas less 
extensive areas such as the rectosigmoid predominated among 
patients without hematological abnormalities.
No association was observed between the type of pharmaco-
logical treatment and the presence of hematological abnormali-
ties (data not shown). This assessment was carried out because 
anemia is considered to be an adverse effect of some drugs used 
for the treatment of IBD, especially sulfasalazine, which inhibits 
folic acid absorption, and azathioprine, which can cause pancy-
topenia and macrocytosis.
There may be a tendency to look upon anemia as an unavoid-
able accompaniment to IBD. Only in recent years has its correction 
been highlighted as a specific therapeutic aim in these patients. 
It should not be assumed that some level of anemia is a normal 
finding in IBD patients. Thus, the World Health Organization 
definitions of anemia apply to patients with IBD.21 For patients in 
remission or with mild disease, laboratory screening should be 
performed every 6 or 12 months. The minimum workup should 
include complete blood count, serum ferritin, serum iron, trans-
ferrin concentration, transferrin saturation, lactate dehydrogenase 
and reticulocyte count. In outpatients with active disease, such 
measurements should be performed at least every three months. 
Patients at risk of vitamin B12 or folic acid deficiency (e.g. small 
bowel disease or resection) need proper surveillance. Serum lev-
els of vitamin B12 and folic acid should be measured at least annu-
ally, or if macrocytosis is present.32 However, even the results from 
recently available tests such as measurement of soluble transfer-
rin receptor indicate that there is a need for other laboratory tests 
that are able to distinguish between IDA and ACD. In this regard, 
standardization of the different kits used for measurement of sol-
uble transferrin receptor, or even the soluble transferrin receptor/
log ferritin ratio, might be a solution for this problem.
CONCLUSIONS
Anemia and/or iron disorders were important systemic compli-
cations in the group of IBD patients studied here. Anemia was 
observed in 20.5% of the patients with Crohn’s disease and in 
23.6% with ulcerative colitis. Anemia of chronic disease in com-
bination with iron deficiency anemia was present in 3% of the 
patients with Crohn’s disease and in 7% of the patients with 
ulcerative colitis. The differential diagnosis between the two most 
prevalent types of anemia, IDA and ACD, was made based on 
clinical data and routine laboratory tests. However, no marker 
that exclusively helped with or confirmed this diagnosis could be 
identified. There was no association between anemia and disease 
location and between anemia and pharmacological treatment. In 
ulcerative colitis cases, anemia was associated with the disease 
activity index.
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